Primary biliary cirrhosis, also known as primary biliary cholangitis, is a chronic liver disease that produces inflammation, fibrosis, and bile duct obstruction, resulting in the loss of tiny bile ducts within the liver. Autoimmunity, infection, and/or genetic predisposition are all possible causes of primary biliary cirrhosis. Itching, osteoporosis, high serum cholesterol, and malabsorption of fat and fat-soluble vitamins are all symptoms of primary biliary cirrhosis, which can progress to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome, or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and might eventually lead the liver to stop functioning completely.
The primary biliary cholangitis therapy market is predicted to develop because of an increase in the number of pipeline studies.
The primary biliary cholangitis treatment market is predicted to grow because of an increase in pipeline research to create prominent medicines for rare diseases such as primary biliary cholangitis. For example, CymaBay Therapeutics, Inc. started a placebo-controlled, randomized phase 3 clinical trial for seladelpar 5-10mg in October 2018. The researchers wanted to see if seladelpar was safe and effective in individuals with primary biliary cholangitis (PBC) and if there was an inadequate response or intolerance to ursodeoxycholic acid (UDCA). The research is expected to be finished in December 2021.
Regional Analysis of the Primary Biliary Cholangitis Treatment Market
The primary biliary cholangitis treatment market is predicted to grow because of an increase in pipeline research to create prominent medicines for rare diseases such as primary biliary cholangitis. For example, CymaBay Therapeutics, Inc. started a placebo-controlled, randomized phase 3 clinical trial for seladelpar 5-10mg in October 2018. The researchers wanted to see if seladelpar was safe and effective in individuals with primary biliary cholangitis (PBC) and if there was an inadequate response or intolerance to ursodeoxycholic acid (UDCA). The research is expected to be finished in December 2021.
Regional Analysis of the Primary Biliary Cholangitis Treatment Market
North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa make up the global primary biliary cholangitis therapy market.
Due to rising endeavors by market participants to create advanced treatment options for PBC, the primary biliary cholangitis treatment market in North America is expected to grow lucratively. For example, in October 2016, TARGET PharmaSolutions, Inc., a U.S.-based company, introduced its TARGET-PBC (Primary Biliary Cholangitis) platform in conjunction with Intercept Pharmaceuticals, Inc. The TARGET-PBC platform was developed to help researchers better understand real-world treatment trends in PBC.
Primary Biliary Cholangitis Treatment Market - Competitive Landscape
Key players operating in the primary biliary cholangitis treatment market include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, Retrophin, Inc., Calliditas Therapeutics AB., and GlaxoSmithKline (GSK) pharmaceutical.
Due to rising endeavors by market participants to create advanced treatment options for PBC, the primary biliary cholangitis treatment market in North America is expected to grow lucratively. For example, in October 2016, TARGET PharmaSolutions, Inc., a U.S.-based company, introduced its TARGET-PBC (Primary Biliary Cholangitis) platform in conjunction with Intercept Pharmaceuticals, Inc. The TARGET-PBC platform was developed to help researchers better understand real-world treatment trends in PBC.
Primary Biliary Cholangitis Treatment Market - Competitive Landscape
Key players operating in the primary biliary cholangitis treatment market include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, Retrophin, Inc., Calliditas Therapeutics AB., and GlaxoSmithKline (GSK) pharmaceutical.
0 Comments